万古霉素耐药肠球菌菌血症:高剂量达托霉素与生存改善相关
该研究为美国退伍军人事务部医院内患者的全国性回顾性队列研究,纳入911例接受达托霉素治疗的万古霉素耐药肠球菌血流感染患者。与高剂量(≥10 mg/kg)相比,标准剂量(6 mg/kg)和中剂量(8 mg/kg)与更差的生存相关,高剂量组30天死亡率更低且微生物清除更快,CPK升高风险无差异。
要点
- 高剂量达托霉素(≥10 mg/kg)与VRE-BSI患者生存改善和微生物清除更快相关。
- 标准剂量(6 mg/kg)和中剂量(8 mg/kg)与高剂量相比生存更差。
- 不同剂量组间CPK升高风险无显著差异。
核心结论
- 高剂量达托霉素与VRE-BSI患者生存改善和微生物清除相关。
研究设计与样本
- 全国性回顾性队列研究,纳入911例住院退伍军人事务部患者,接受标准剂量(6 mg/kg,n=709)、中剂量(8 mg/kg,n=142)或高剂量(≥10 mg/kg,n=60)达托霉素治疗VRE-BSI。
主要发现
- 与高剂量相比,标准剂量(HR 2.68,95%CI 1.33-3.06,P=.002)和中剂量(HR 2.66,95%CI 1.33-3.92,P=.003)与更差生存相关。
- 调整混杂后,标准剂量(aHR 2.58,95%CI 1.27-4.88,P=.004)和中剂量(aHR 2.52,95%CI 1.27-5.00,P=.008)与更差生存的关联持续存在。
- 各组间CPK升高风险无差异(P=.504)。
临床怎么用
- 对于VRE-BSI患者,在评估病情和耐药情况后,可考虑使用高剂量达托霉素(≥10 mg/kg)以改善生存和微生物清除。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vancomycin-resistant Enterococcus bloodstream infections (VRE-BSIs) are associated with significant mortality. Daptomycin exhibits concentration-dependent activity vs VRE in vitro, yet the clinical impact of higher-dose strategies remains unclear. METHODS: We performed a national retrospective cohort study of hospitalized Veterans Affairs patients treated with standard-dose (6 mg/kg total body weight), medium-dose (8 mg/kg total body weight), or high-dose (≥10 mg/kg total body weight) daptomycin for VRE-BSI. Patient-related, microbiological, and outcomes data were abstracted from clinical databases. The primary outcome was overall survival, evaluated by Cox regression. Secondary outcomes included 30-day mortality, time to microbiological clearance, and creatine phosphokinase (CPK) elevation. RESULTS: A total of 911 patients were included (standard dose, n = 709; medium dose, n = 142; high dose, n = 60). Compared to high-dose daptomycin, both standard-dose (hazard ratio [HR], 2.68; 95% confidence interval; [CI], 1.33-3.06; P = .002) and medium-dose (HR, 2.66; 95% CI, 1.33-3.92; P = .003) daptomycin were associated with poorer survival. After adjusting for confounders, the relationship between poorer survival and standard-dose (adjusted HR [aHR], 2.58; 95% CI, 1.27-4.88; P = .004) and medium-dose (aHR, 2.52; 95% CI, 1.27-5.00; P = .008) daptomycin persisted. Thirty-day mortality was significantly lower among high-dose daptomycin-treated patients compared with other dosing strategies (risk ratio, 0.83; 95% CI, .74-.94; P = .015). Compared with standard-dose daptomycin, both medium-dose (HR, 0.78; 95% CI, .55-.90; P = .012) and high-dose daptomycin (HR, 0.70; 95% CI, .41-.84; P = .006) were associated with significantly improved microbiological clearance. No difference in the risk of CPK elevation was observed between the treatment groups (P = .504). CONCLUSIONS: High-dose daptomycin was associated with improved survival and microbiological clearance in VRE-BSI.
引用
- Britt NS, Potter EM, Patel N, et al. Comparative Effectiveness and Safety of Standard-, Medium-, and High-Dose Daptomycin Strategies for the Treatment of Vancomycin-Resistant Enterococcal Bacteremia Among Veterans Affairs Patients. Clin Infect Dis. 2017. PMID: 28011602. doi:10.1093/cid/ciw815
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。